The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.
 
Praful Ravi
No Relationships to Disclose
 
Lucia Kwak
No Relationships to Disclose
 
John Armstrong
No Relationships to Disclose
 
Veronique Beckendorf
No Relationships to Disclose
 
Joseph Chin
No Relationships to Disclose
 
Anthony Victor D'Amico
No Relationships to Disclose
 
David P. Dearnaley
Consulting or Advisory Role - Janssen Oncology
Patents, Royalties, Other Intellectual Property - Abiraterone acetate was developed at The Institute of Cancer Research, which therefore has a commercial interest in the development of this agent. Professor Dearnaley is on the Institute’s Rewards to Inventors list for abiraterone acetate. (Inst); Patent issued EP1933709B1 (location and stabilisation device)
 
James William Denham
No Relationships to Disclose
 
Savino Mauro Di Stasi
No Relationships to Disclose
 
Silke Gillessen
Consulting or Advisory Role - AAA HealthCare (Inst); Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Daiichi Sankyo Europe GmbH (Inst); Modra Pharmaceuticals (Inst); MSD Oncology; MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Orion (Inst); PeerVoice (Inst); Pfizer (Inst); Telix Pharmaceuticals (Inst); TOLREMO (Inst); WebMD/Medscape (Inst)
Speakers' Bureau - ASCO GU (Inst); ESMO; ESMO (Inst); German-speaking European School of Oncology (DESO); Silvia Grasso Consulting (Inst); Swiss Academy of Multidisciplinary Oncology (SAMO); Swiss Group for Clinical Cancer Research (SAKK); Swiss Group for Clinical Cancer Research (SAKK) (Inst)
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - Cold Spring Harbor Laboratory (Inst); ProteoMediX
 
Himanshu Lukka
No Relationships to Disclose
 
Nicolas Mottet Auselo
No Relationships to Disclose
 
Pascal Pommier
No Relationships to Disclose
 
Wendy Seiferheld
No Relationships to Disclose
 
Matthew R. Sydes
Honoraria - Janssen; Janssen; Lilly; Sanofi
Research Funding - Astellas Pharma; Clovis Oncology; Janssen-Cilag; Novartis; Pfizer; Sanofi
 
Bertrand F. Tombal
Honoraria - AAA/Endocyte/Novartis; Amgen; Astellas Pharma; AstraZeneca; Bayer; Ferring; Janssen; MSD Oncology; Myovant Sciences; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Myovant Sciences; Pfizer/Astellas; Sanofi; Steba Biotech; Takeda
Speakers' Bureau - Amgen; Astellas Pharma; Astellas Pharma; Janssen
Research Funding - Ferring (Inst)
Expert Testimony - Steba Biotech
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi
 
Almudena Zapatero
Consulting or Advisory Role - Bayer
Speakers' Bureau - Astellas Pharma; Janssen
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Ipsen
 
Meredith M. Regan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Debiopharm Group (Inst); Ipsen (Inst); Tersera; Tolmar
Research Funding - AstraZeneca (Inst); Bayer (Inst); bioTheranostics (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); TerSera (Inst)
 
Wanling Xie
Consulting or Advisory Role - Convergent Therapeutics
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination